Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Response to the comment by Gando on the updated definition and scoring of disseminated intravascular coagulation.

Journal of thrombosis and haemostasis : JTH·2026

Same author

Laboratory and Medicine 2.1: Care for What You Wish for.

International journal of laboratory hematology·2026

Same author

Comparative effects of flow- versus volume-controlled one-lung ventilation on gas exchange and respiratory system mechanics in thoracic surgery: A randomised controlled clinical trial.

European journal of anaesthesiology·2025

Same author

Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.

Journal of thrombosis and haemostasis : JTH·2025

Same author

Organ Dysfunction in Sepsis-associated Intravascular Coagulation.

Juntendo Iji zasshi = Juntendo medical journal·2024

Same author

Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?

Journal of thrombosis and haemostasis : JTH·2024

Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026

Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026

Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026

Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026

Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026

Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 11, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

Sepsis and thrombosis.

Marcel Levi¹, Marcus Schultz, Tom van der Poll

¹Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. m.m.levi@amc.uva.nl

Seminars in Thrombosis and Hemostasis

|April 30, 2013

Summary

This summary is machine-generated.

Severe infections and sepsis can activate blood clotting, potentially worsening outcomes for patients with thrombophilia, a condition causing excessive clotting. Strategies inhibiting coagulation activation show promise in managing these severe cases.

More Related Videos

A Data-Driven Approach to Quantifying Immune States in Sepsis

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

Related Experiment Videos

Last Updated: May 11, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

A Data-Driven Approach to Quantifying Immune States in Sepsis

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

Area of Science:

Medical Science
Hematology
Infectious Diseases

Background:

Severe infection and sepsis commonly activate the coagulation system, leading to thrombosis.
Coagulation abnormalities in sepsis vary from mild platelet reduction to severe disseminated intravascular coagulation (DIC).
DIC involves widespread microvascular thrombosis and bleeding, often presenting as multiple organ dysfunction.

Purpose of the Study:

To explore the hypothetical impact of thrombophilia on coagulopathy severity in sepsis.
To investigate if thrombophilia exacerbates sepsis-induced coagulation disorders and clinical outcomes.
To review strategies for inhibiting coagulation activation in severe inflammation and sepsis.

Main Methods:

Review of existing literature on coagulation activation in sepsis and thrombophilia.
Analysis of the pathogenesis of thrombosis in severe inflammation.
Examination of experimental and clinical studies on coagulation inhibition strategies.

Main Results:

Activation of coagulation is a frequent complication of severe infection and sepsis.
Thrombophilia, a prothrombotic state, may lead to more severe coagulopathy in septic patients.
Inhibition of coagulation activation has shown favorable results in experimental and clinical settings.

Conclusions:

Septic patients with thrombophilia may experience more severe coagulopathy and adverse outcomes.
Understanding coagulation pathogenesis in sepsis informs therapeutic strategies.
Coagulation inhibition presents a promising approach for managing sepsis-associated thrombosis.